NP
AZN icon

NorthRock Partners’s AstraZeneca AZN Stock Holding History

NorthRock Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$659K Buy
+3,339
New +$644K 0.01% 371
2025
Q4 		– Sell
-2,233
Closed -$343K – 647
2025
Q3 		$343K Sell
2,233
-53
-2% -$8.02K 0.01% 656
2025
Q2 		$319K Sell
2,286
-201
-8% -$28.2K 0.01% 517
2025
Q1 		$366K Buy
2,487
+646
+35% +$93.5K 0.01% 431
2024
Q4 		$241K Buy
1,841
+150
+9% +$21K 0.01% 532
2024
Q3 		$263K Buy
1,691
+25
+2% +$4.04K 0.01% 540
2024
Q2 		$260K Sell
1,666
-6
-0.4% -$903 0.01% 513
2024
Q1 		$227K Sell
1,672
-361
-18% -$47.8K 0.01% 552
2023
Q4 		$274K Buy
+2,033
New +$264K 0.01% 475
2023
Q3 		– Sell
-1,578
Closed -$226K – 355
2023
Q2 		$226K Sell
1,578
-69
-4% -$10.2K 0.02% 269
2023
Q1 		$229K Buy
+1,647
New +$222K 0.02% 282
2022
Q3 		– Sell
-3,884
Closed -$513K – 301
2022
Q2 		$513K Buy
3,884
+66
+2% +$8.66K 0.05% 150
2022
Q1 		$507K Buy
3,818
+292
+8% +$35K 0.05% 172
2021
Q4 		$411K Sell
3,526
-175
-5% -$20.6K 0.03% 200
2021
Q3 		$444K Buy
3,701
+471
+15% +$54.8K 0.04% 167
2021
Q2 		$387K Hold
3,230
– – 0.03% 167
2021
Q1 		$321K Sell
3,230
-2,073
-39% -$208K 0.03% 166
2020
Q4 		$530K Sell
5,303
-4,564
-46% -$483K 0.05% 123
2020
Q3 		$1.08M Buy
9,867
+6,832
+225% +$760K 0.12% 71
2020
Q2 		$321K Sell
3,035
-176
-5% -$18.2K 0.04% 151
2020
Q1 		$287K Sell
3,211
-1,011
-24% -$95.2K 0.04% 146
2019
Q4 		$421K Buy
4,222
+526
+14% +$49.5K 0.04% 169
2019
Q3 		$329K Buy
+3,696
New +$320K 0.04% 155

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

NorthRock Partners's AZN Position: Q1 2026 in Review

NorthRock Partners opened a new position in AstraZeneca (AZN) in Q1 2026: 3,339 shares worth $659K. The stake represents 0.01% of the portfolio and ranks #371 among its holdings. This is a return to the name: NorthRock Partners previously reported a position in AZN as recently as Q3 2025.

NorthRock Partners first reported a position in AZN in Q3 2019 and has held it in 23 quarters since. The position peaked at $1.08M in Q3 2020. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • NorthRock Partners held 3,339 shares of AstraZeneca worth $659K as of Q1 2026.
  • AstraZeneca was a new NorthRock Partners position in Q1 2026.
  • AstraZeneca made up 0.01% of NorthRock Partners's portfolio in Q1 2026, its #371 holding.
  • NorthRock Partners first reported a position in AstraZeneca in Q3 2019 and has held it in 23 quarters since.
  • NorthRock Partners's AstraZeneca position peaked at $1.08M in Q3 2020.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on NorthRock Partners's 13F filing for Q1 2026, filed 15 May 2026.